foxo4-dri user experiences anecdotal reports is fascinating, but was never intended for human use, what are the takeaways? - longevity Senolytic Peptide FOXO4-DRI Selectively Removes
Description
Frequency varies by peptide: BPC-157 is typically dosed twice daily

Immune Modulation: The peptide's effects on inflammatory pathways suggest caution for: Active autoimmune conditions Immunocompromised individuals Those taking immunomodulatory medications Populations Requiring Extra Caution Avoid or Use Extreme Caution: Active cancer or history of cancer Pregnancy or breastfeeding Children and adolescents Severe cardiovascular disease Active infections Immediately pre or post-surgery (without medical guidance) Drug Interactions Theoretical Interactions Given BPC-157's mechanisms, theoretical interactions exist with: Medications Affecting NO System: Nitrates (nitroglycerin, isosorbide) PDE5 inhibitors (sildenafil, tadalafil) Some blood pressure medications Reasoning: Combined NO system effects Anticoagulants and Antiplatelets: Warfarin Aspirin Clopidogrel Direct oral anticoagulants Reasoning: Angiogenic effects may affect bleeding Growth Hormone and Related: HGH IGF-1 Other growth-promoting compounds Reasoning: Additive growth factor effects Immunomodulators: Corticosteroids TNF-alpha inhibitors Other immunosuppressants Reasoning: Overlapping immune effects NSAIDs A Special Case Interestingly, while drug interactions are generally concerning, research suggests BPC-157 may protect against NSAID damage

Dose optimization requires baseline biomarker testing and provider oversight to ensure efficacy and safety

doi: 10.1002/2327-6924.12247

The patient should also not have any contraindications to VA ECMO (listed here)

[DOI] [PMC free article] [PubMed] [Google Scholar] 49.Whitmore L, Wallace BA
